Inventor
BELLOVIN DAVID
US14 patents
⚠️ This page may combine multiple inventors who share the name “BELLOVIN DAVID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
FIVE PRIME THERAPEUTICS INC
12 patentsUS9765147B2Sep 19, 2017
Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC25 citations93
US10618967B2Apr 14, 2020
Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC5 citations83
US10221244B2Mar 5, 2019
Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC10 citations83
US10273281B2Apr 30, 2019
CD80 extracellular domain polypeptides and their use in cancer treatment
FIVE PRIME THERAPEUTICS INC7 citations81
US11306144B2Apr 19, 2022
B7-H4 antibodies and methods of use thereof
FIVE PRIME THERAPEUTICS INC6 citations80
US11814431B2Nov 14, 2023
B7-H4 antibodies and methods of use thereof
FIVE PRIME THERAPEUTICS INC3 citations68
US11559583B2Jan 24, 2023
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC0 citations62
US11566076B2Jan 31, 2023
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
FIVE PRIME THERAPEUTICS INC0 citations61
US12365719B2Jul 22, 2025
CD80 extracellular domain polypeptides and their use in cancer treatment
FIVE PRIME THERAPEUTICS INC0 citations59
US11098103B2Aug 24, 2021
CD80 extracellular domain polypeptides and their use in cancer treatment
FIVE PRIME THERAPEUTICS INC0 citations59
US11421034B2Aug 23, 2022
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
FIVE PRIME THERAPEUTICS INC0 citations46
US9775881B2Oct 3, 2017
Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
FIVE PRIME THERAPEUTICS INC1 citations44